このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Everycell's Effect on DNA Damage, Inflammation, and Stress

2014年5月22日 更新者:John E. Lewis、University of Miami

The Effect of Dietary Supplementation on DNA Damage, Inflammation, Stress, and Related Factors Important in Somatic and Stem Cell Senescence in Healthy Adults

The investigators are conducting this research because they want to determine if a dietary supplement, called Everycell™, has an effect on the functioning of the study participants' cells. The results of this research will be used to help develop additional strategies for trying to fight the effects of aging. The primary purpose of this study is to determine the effectiveness of Everycell™ compared to placebo (a pill that does nothing) on DNA damage, inflammation, stress, and related factors. Taking Everycell™ is not a medical prescription, treatment, or cure for any known disease or condition.

Helping patients' nutritional status is important to prevent the continued worsening of chronic diseases and also to counteract the effects of aging. Americans also have difficulties with compliance to prescription medications due to their toxicity and side effects. This study aims to learn more about how a dietary supplement may improve nutritional status and enable the body to normalize cellular functioning, which may improve quality of life. The results of this research will be used to determine if Everycell™ is beneficial for overall cellular health and to counteract the effects of aging.

調査の概要

詳細な説明

The proposed study is a 6-week, randomized, double-blind, placebo-controlled trial to evaluate the effect of everycell compared to placebo on DNA damage, inflammation, stress, and related factors in 30 healthy adults (18-55 years of age). Participants will be assessed at baseline, 4 weeks (end of intervention), and 6 weeks (2-week washout period), and the study will consist of two treatment arms, including: (a) Everycell and (b) placebo. Additionally, the study will examine subject health-related quality of life (QoL).

Specific Aim. Test the effect of Everycell compared to placebo on DNA damage, inflammation, stress, and related factors in a sample of healthy adults.

Hypothesis. The Everycell group will demonstrate improvements in DNA damage, inflammation, stress, and related factors at 4 and 6-week follow-ups compared to placebo.

Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.

No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture. The components of everycell should be harmless without significant food allergies. No serious, untoward side effects have been reported to the company by consumers nor observed during previous human studies. If any side effect does occur, the remedy is to discontinue until asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2 days, if uneventful, until full dosage is achieved. A toxicology search for each component reveals no unique toxicity characteristic of the materials. As reported by CellHealth Institute, the manufacturer of the product, many customers currently use Everycell, and CellHealth Institute is unaware of significant toxicities.

CellHealth Institute applies the latest scientific methods to ensure the value and safety of their raw materials. CellHealth Institute products are manufactured in state-of-the-art facilities, under strict quality control and environmental protection standards.

Participants will incur no additional appreciable psychological or social risks by participating in this study, although they may undergo psychological and physical discomfort sometimes. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.

Alternatives to this study for improving DNA damage, inflammation, and stress include prescription medications, exercise, dietary modification, and other nutritional supplements. The risks of medications can be very significant, including life-threatening, but the risk of taking nutritional supplements is not totally understood, since they are not regulated by the US Food and Drug Administration. Medications and nutritional supplements, as part of a change in lifestyle behaviors, may also prove to be beneficial for DNA damage, inflammation, and stress, but their long-term use has unknown consequences.

The information obtained in this study will help in determining the efficacy of using a nutritional supplement for improving DNA damage, inflammation, and stress outcomes. By participating in the study, subjects may experience improved DNA damage, inflammation, and stress. The risk of participating in this study is reasonable because of the potential enhancements in DNA damage, inflammation, and stress with improved nutritional status.

研究の種類

介入

入学 (実際)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Florida
      • Miami、Florida、アメリカ、33136
        • University of Miami Miller School of Medicine, Clinical Research Building

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~55年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Be between the ages of 18 and 55
  • Live independently without medical assistance
  • Willing to provide informed consent to participate in the study
  • Willing to follow our procedures and requirements for the study, including:

    1. providing blood, urine, and saliva samples
    2. completing other assessments
  • Patients may take a similar dietary supplement as the one used in the study, but they must stop taking all similar dietary supplements 2 weeks prior to starting the study and for the 6 weeks duration of the study.

Exclusion Criteria:

  • Patients need to be free of major medical conditions, such as neurological, cardiovascular, pulmonary, renal, endocrine, thyroid, hepatic, autoimmune, or bone/joint disorders or conditions; psychiatric diagnoses or psychotic disorders, and have no gastrointestinal disorders that could affect how the dietary supplement is absorbed by their body.
  • Cannot participate in another similar research trial within 30 days of participating in this study
  • Cannot be a smoker or have stopped smoking less than 6 months ago
  • Cannot currently be taking any chemotherapy or radiation treatment for cancer
  • Cannot be diagnosed with a terminal illness
  • Cannot be diagnosed with insulin-dependent diabetes and/or be taking metformin
  • Cannot be HIV positive
  • If female, the patient cannot currently be pregnant, breastfeeding, or intending to become pregnant within the next month

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Everycell™
Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
プラセボコンパレーター:Placebo
Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
他の名前:
  • シュガーピル

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Fructosamine at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Protein Thiol Test at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Homocysteine at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Telomere Length at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Cluster of Differentiation 8 at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in 8-hydroxydeoxyguanosine at 4 weeks
時間枠:Baseline, 4-week follow-up
Urine sample for 8-OHdG and 8-epi-PGF-2-alpha
Baseline, 4-week follow-up
Change from Baseline in 8-epi-PGF-2-alpha at 4 weeks
時間枠:Baseline, 4-week follow-up
Urine sample for 8-OHdG and 8-epi-PGF-2-alpha
Baseline, 4-week follow-up
Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 4 weeks
時間枠:Baseline, 4-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 4-week follow-up
Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Fructosamine at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Protein Thiol Test at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Homocysteine at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Telomere Length at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Cluster of Differentiation 8 at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in 8-hydroxydeoxyguanosine at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in 8-epi-PGF-2-alpha at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up
Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 6 weeks
時間枠:Baseline, 6-week follow-up
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Baseline, 6-week follow-up

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in Systolic Blood Pressure at 4 weeks
時間枠:Baseline, 4-week follow-up
Systolic and diastolic blood pressure measured.
Baseline, 4-week follow-up
Change from Baseline in Pulse at 4 weeks
時間枠:Baseline, 4-week follow-up
Baseline, 4-week follow-up
Change from Baseline in Waist Circumference at 4 weeks
時間枠:Baseline, 4-week follow-up
Measure of body composition: waist circumference (cm).
Baseline, 4-week follow-up
Change from Baseline in Hip Circumference at 4 weeks
時間枠:Baseline, 4-week follow-up
Measure of body composition: hip circumference (cm).
Baseline, 4-week follow-up
Change from Baseline in Weight at 4 weeks
時間枠:Baseline, 4-week follow-up
Measure of body composition: weight.
Baseline, 4-week follow-up
Change from Baseline in Height at 4 weeks
時間枠:Baseline, 4-week follow-up
Measure of body composition: height.
Baseline, 4-week follow-up
Change from Baseline in Body Mass Index at 4 weeks
時間枠:Baseline, 4-week follow-up
Measure of body composition: height and weight to assess BMI.
Baseline, 4-week follow-up
Change from Baseline in International Physical Activity Questionnaire at 4 weeks
時間枠:Baseline, 4-week follow-up
Baseline, 4-week follow-up
Change from Baseline in SF-36v2™ Health Survey at 4 weeks
時間枠:Baseline, 4-week follow-up
Baseline, 4-week follow-up
Change from Baseline in Systolic Blood Pressure at 6 weeks
時間枠:Baseline, 6-week follow-up
Systolic and diastolic blood pressure measured.
Baseline, 6-week follow-up
Change from Baseline in Diastolic Blood Pressure at 4 weeks
時間枠:Baseline, 4-week follow-up
Systolic and diastolic blood pressure measured.
Baseline, 4-week follow-up
Change from Baseline in Diastolic Blood Pressure at 6 weeks
時間枠:Baseline, 6-week follow-up
Systolic and diastolic blood pressure measured.
Baseline, 6-week follow-up
Change from Baseline in Pulse at 6 weeks
時間枠:Baseline, 6-week follow-up
Baseline, 6-week follow-up
Change from Baseline in Waist Circumference at 6 weeks
時間枠:Baseline, 6-week follow-up
Measure of body composition: waist circumference (cm).
Baseline, 6-week follow-up
Change from Baseline in Hip Circumference at 6 weeks
時間枠:Baseline, 6-week follow-up
Measure of body composition: hip circumference (cm).
Baseline, 6-week follow-up
Change from Baseline in Weight at 6 weeks
時間枠:Baseline, 6-week follow-up
Measure of body composition: weight.
Baseline, 6-week follow-up
Change from Baseline in Height at 6 weeks
時間枠:Baseline, 6-week follow-up
Measure of body composition: height.
Baseline, 6-week follow-up
Change from Baseline in Body Mass Index at 6 weeks
時間枠:Baseline, 6-week follow-up
Measure of body composition: height and weight to assess BMI.
Baseline, 6-week follow-up
Change from Baseline in International Physical Activity Questionnaire at 6 weeks
時間枠:Baseline, 6-week follow-up
Baseline, 6-week follow-up
Change from Baseline in SF-36v2™ Health Survey at 6 weeks
時間枠:Baseline, 6-week follow-up
Baseline, 6-week follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2013年12月1日

一次修了 (実際)

2014年4月1日

研究の完了 (実際)

2014年4月1日

試験登録日

最初に提出

2014年1月2日

QC基準を満たした最初の提出物

2014年1月9日

最初の投稿 (見積もり)

2014年1月10日

学習記録の更新

投稿された最後の更新 (見積もり)

2014年5月23日

QC基準を満たした最後の更新が送信されました

2014年5月22日

最終確認日

2014年5月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 20130411 (その他の識別子:Amgen Study ID)

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する